PB2267: TRIAL IN PROGRESS: PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF ODRONEXTAMAB VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA (OLYMPIA-1)

• Stefano Luminari,
• Tae Min Kim,
• Ashish Risal,
• Manjusha Namuduri,
• Jingxian Cai,
• Bertha Fearon-Chalet,
• Min Zhu,
• Sushmita Mukherjee,
• Jurriaan Brouwer-Visser,
• Aafia Chaudhry,
• Hesham Mohamed,
• Srikanth Ambati,
• Umberto Vitolo

Affiliations

Stefano Luminari

1 Division of Hematology, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy

Tae Min Kim

2 Seoul National University Hospital, Seoul, Korea, Rep. of South

Ashish Risal

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Manjusha Namuduri

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Jingxian Cai

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Bertha Fearon-Chalet

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Min Zhu

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Sushmita Mukherjee

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Jurriaan Brouwer-Visser

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Aafia Chaudhry

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Hesham Mohamed

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Srikanth Ambati

3 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States

Umberto Vitolo

4 Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Turin), Italy